Sanofi-Aventis (SNY) Says Multaq Study Shows 24% Cut in Cardio Hospitalization/Death -Bloomberg

FREE Breaking News Alerts from StreetInsider.com!

More News related to SNY

Sanofi's (SNY) Genzyme Reports Continued Endpoint Improvement for Eliglustat Tartrate in Phase 2 Trials
Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints
Sanofi: 2011 Results Benefit from Genzyme Acquisition
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Sanofi CEO Chris Viehbacher Comments on 2011 Results

More News related to Corporate News

May 15, 2008 12:52 PM EDT

Bloomberg is reporting that Sanofi-Aventis (NYSE: SNY) said Multaq results show statistical significance: Multaq reduced cardio hospitalization/death by 24%.

Create E-mail AlertRelated Categories

Corporate News

Stocks Mentioned

SNY 37.57

+0.34 +0.91%
Volume: 1,620,159
Track SNY

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

Follow StreetInsider.com On Twitter